JP2001503754A - 化粧品及び医薬品分野でのポテンチラ・エレクタ抽出物の使用 - Google Patents
化粧品及び医薬品分野でのポテンチラ・エレクタ抽出物の使用Info
- Publication number
- JP2001503754A JP2001503754A JP52110698A JP52110698A JP2001503754A JP 2001503754 A JP2001503754 A JP 2001503754A JP 52110698 A JP52110698 A JP 52110698A JP 52110698 A JP52110698 A JP 52110698A JP 2001503754 A JP2001503754 A JP 2001503754A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- composition
- use according
- skin
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 61
- 240000000103 Potentilla erecta Species 0.000 title claims abstract description 32
- 239000002537 cosmetic Substances 0.000 title claims abstract description 23
- 235000016551 Potentilla erecta Nutrition 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title description 4
- 229920001436 collagen Polymers 0.000 claims abstract description 36
- 102000008186 Collagen Human genes 0.000 claims abstract description 35
- 108010035532 Collagen Proteins 0.000 claims abstract description 35
- 210000003491 skin Anatomy 0.000 claims abstract description 23
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 20
- 210000002510 keratinocyte Anatomy 0.000 claims abstract description 15
- 210000004209 hair Anatomy 0.000 claims abstract description 12
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 11
- 230000037303 wrinkles Effects 0.000 claims abstract description 10
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 7
- 230000001737 promoting effect Effects 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 210000002615 epidermis Anatomy 0.000 claims description 12
- 210000004207 dermis Anatomy 0.000 claims description 11
- 241000196324 Embryophyta Species 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 230000009759 skin aging Effects 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- 230000035876 healing Effects 0.000 claims description 4
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 claims description 4
- 230000004089 microcirculation Effects 0.000 claims description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 4
- 229930002330 retinoic acid Natural products 0.000 claims description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 claims description 3
- 244000146462 Centella asiatica Species 0.000 claims description 3
- 235000004032 Centella asiatica Nutrition 0.000 claims description 3
- 208000001840 Dandruff Diseases 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims description 3
- 229940106189 ceramide Drugs 0.000 claims description 3
- 229960005443 chloroxylenol Drugs 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 230000003014 reinforcing effect Effects 0.000 claims description 3
- 230000037393 skin firmness Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 241001291325 Celeus Species 0.000 claims description 2
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 claims description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 2
- 244000061508 Eriobotrya japonica Species 0.000 claims description 2
- 235000009008 Eriobotrya japonica Nutrition 0.000 claims description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 2
- 241000213914 Tephrosia <angiosperm> Species 0.000 claims description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims description 2
- 229940022757 asiaticoside Drugs 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 claims description 2
- 150000001783 ceramides Chemical class 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 229960002173 citrulline Drugs 0.000 claims description 2
- 235000013477 citrulline Nutrition 0.000 claims description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 210000002744 extracellular matrix Anatomy 0.000 claims description 2
- -1 glycoceramides Chemical class 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229960001238 methylnicotinate Drugs 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 229960001755 resorcinol Drugs 0.000 claims description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 229960000278 theophylline Drugs 0.000 claims description 2
- 229960002898 threonine Drugs 0.000 claims description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 235000019149 tocopherols Nutrition 0.000 claims description 2
- 229940075420 xanthine Drugs 0.000 claims description 2
- 229940043810 zinc pyrithione Drugs 0.000 claims description 2
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 claims description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 4
- 230000002378 acidificating effect Effects 0.000 claims 2
- 239000002981 blocking agent Substances 0.000 claims 2
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims 1
- 240000005528 Arctium lappa Species 0.000 claims 1
- 235000003130 Arctium lappa Nutrition 0.000 claims 1
- 240000003291 Armoracia rusticana Species 0.000 claims 1
- 235000011330 Armoracia rusticana Nutrition 0.000 claims 1
- 241001660259 Cereus <cactus> Species 0.000 claims 1
- 240000003890 Commiphora wightii Species 0.000 claims 1
- 241001092070 Eriobotrya Species 0.000 claims 1
- 241001092489 Potentilla Species 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 229960001679 octinoxate Drugs 0.000 claims 1
- 230000036558 skin tension Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
- 230000003752 improving hair Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 2
- 238000004113 cell culture Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 10
- 239000000401 methanolic extract Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 206010040954 Skin wrinkling Diseases 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 108010017377 Collagen Type VII Proteins 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 102000004510 Collagen Type VII Human genes 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- 238000004873 anchoring Methods 0.000 description 4
- 239000006286 aqueous extract Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229940072107 ascorbate Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 201000010251 cutis laxa Diseases 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 3
- 239000004137 magnesium phosphate Substances 0.000 description 3
- 229960002261 magnesium phosphate Drugs 0.000 description 3
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 3
- 235000010994 magnesium phosphates Nutrition 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 241000208843 Arctium Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- YDDGBJGRSLHCOE-UHFFFAOYSA-N Cepharantine Natural products C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC(C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2C1NCC3 YDDGBJGRSLHCOE-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 101001010513 Homo sapiens Leukocyte elastase inhibitor Proteins 0.000 description 1
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 description 1
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241001077909 Sigesbeckia Species 0.000 description 1
- 206010040851 Skin fragility Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- YVPXVXANRNDGTA-VMPREFPWSA-N cepharantine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-VMPREFPWSA-N 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- 229940090813 madecassoside Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000590 phytopharmaceutical Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Birds (AREA)
- Medical Informatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Alternative & Traditional Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 真皮−表皮結合を補強することにより真皮と表皮との固着を改善すること を目的として、化粧学的に許容される媒体を含む化粧用組成物に配合される化粧 剤としての、植物ポテンチラ・エレクタ(Potentilla erecta )の抽出物の使用。 2. コラーゲンVIIの形成を促進することを目的として、化粧学的に許容さ れる媒体を含む化粧用組成物に配合される化粧剤としての、植物ポテンチラ・エ レクタの抽出物の使用。 3. 組成物は、皮膚の張りを得ること、皮膚の老化の徴候の出現を予防し若し くは遅らせること、しわの出現を遅らせること、又は、その深さを減少させるこ とを目的とするものである請求項1又は2記載の使用。 4. 皮膚の老化は、特に太陽光の照射による、光線作用性の老化である請求項 3記載の使用。 5. 化粧剤は、毛髪の状態を改善することを目的とするものである請求項2記 載の使用。 6. 真皮と表皮との固着における欠陥に起因する病状、特に真皮−表皮結合の 弱化に起因する病状を治療することを目的とする薬用組成物、特に皮膚科用組成 物を調製するための植物ポテンチラ・エレクタの抽出物の使用。 7. コラーゲンVIIの形成における機能不全に起因する症状又は病状を治療 することを目的とする薬用組成物、特に皮膚科用組成物を調製するための植物ポ テンチラ・エレクタの抽出物の使用。 8. 組成物は、表皮水庖症の治療を目的とするものである請求項6又は7記載 の使用。 9. 組成物は、場合によっては局所治療用処置の補足として、外傷の癒合を改 善するために、特に癒合の前後での皮膚の質を改善するために、外傷を治療する ことを目的とするものである請求項6又は7記載の使用。 10. 抽出物は、水、C1〜C4アルコール、C2〜C6グリコール又はこれら溶 媒の混合物、特に水アルコール混合物又は水グリコール混合物、からなる群より 選択される溶媒を用いた抽出によって得られたものである請求項1、2、3、4 、5、6、7、8又は9記載の使用。 11. 溶媒は水である請求項10記載の使用。 12. アルコールは、メタノール又はエタノールである請求項10記載の使用 。 13. グリコールは、エチレングリコール、プロピレングリコール及びブチレ ングリコールからなる群より選択されるものである請求項10記載の使用。 14. 抽出物は、ブチレングリコールを用いた抽出によって得られたものであ る請求項13記載の使用。 15. 抽出物は、この植物の根茎から得られたものである請求項1〜14記載 の使用。 16. 組成物は、前記組成物の全重量に対して、抽出物を0.0001重量% 〜5重量%、好ましくは0.01重量%〜0.5重量%含有するものである請求 項1〜15記載の使用。 17. 組成物は、皮膚の細胞外マトリックスの構成成分の合成を促進する物質 を少なくとも1つ更に含有するものである請求項1〜16記載の使用。 18. 物質は、ビタミン、特にA及びC群のビタミン並びにエステル等のこれ らの誘導体、トコフェロール、キサンチン、特にカフェイン又はテオフィリン、 レチノイド、特にビタミンA酸、センテラ・アシアチカ(centella a siatica)の抽出物、アシアチン酸(asiatic acid)、マデ カシン酸(madecassic acid)、及び、アシアチコサイド(as iaticoside)又はマデカソサイド(madecassoside)等 のこれらのグリコシル化誘導体、シーゲスベッキア・オレエンタリス(Sieg esbeckia orientalis)の抽出物、コミフォラ・ムカル(C ommiphora mukul)の抽出物、並びに、エリオボトリャ・ジャポ ニカ(Eriobotrya japonica)の抽出物からなる群より選択 されたものである請求項17記載の使用。 19. 組成物は、脂肪族C3〜C12アルファ−ヒドロキシ酸、特にクエン酸、 リンゴ酸及び乳酸、アミノ酸、特にアルギニン、シトルリン及びトレオニン、セ ラミド、グリコセラミド、リン脂質、やせ薬、特にフォルスコリン、セレウス( Celeus)の抽出物、テフロシア(Tephrosia)の抽出物、抗伸展 線剤、特にマロニエの実の抽出物及びエスシン(escine)、微小循環を保 護し又は改善する薬剤、特にギンクゴ・ビローバ(Ginkgo Biloba )のビオフラボノイド、並びに、遮光剤、特に酸化チタン、Parsol MC X及び植物由来の遮光剤からなる群より選択される少なくとも1つの物質を更に 含有するものである請求項1〜18記載の使用。 20. 組成物は、アークティウム・ラッパ(Arctium lappa)の 抽出物、クロロキシレノール、レゾルシノール又は亜鉛ピリチオン等のふけ防止 剤、5α−リダクターゼ阻害剤等の抗脂漏剤、特にピゲヌム・アフリカヌム(P ygenum africanum)の抽出物、並びに、セファランチン及びニ コチン酸メチル等の、血液の微小循環を促進する薬剤からなる群より選択される 少なくとも1つの他の有効成分を更に含有するものである請求項1〜18記載の 使用。 21. 真皮−表皮結合の補強による真皮と表皮との固着の改善を得ること、又 は、コラーゲンVIIの形成を促進することを目的とする化粧処置方法であって 、化粧学的有効量の植物ポテンチラ・エレクタの抽出物を、化粧学的に許容され る賦形剤を含む組成物に含有させて適用することを特徴とする化粧処置方法。 22. 皮膚の張りを得ること、皮膚の老化の徴候の出現を防止し若しくは遅ら せること、しわの出現を遅らせること又はその深さを減少させるために、化粧学 的有効量の植物ポテンチラ・エレクタの抽出物を、化粧学的に許容される賦形剤 を含む組成物に含有させて適用することからなる請求項21記載の化粧処置方法 。 23. コラーゲンVIIの合成促進を達成するために、有効濃度の植物ポテン チラ・エレクタの抽出物を培養培地に導入することを特徴とする、培養細胞、特 にヒト角化細胞又はヒト繊維芽細胞の処置方法。 24. 抽出物は、培養培地の全重量に対して、0.0001重量%〜1重量% の濃度で導入する請求項23記載の処置方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR96/13585 | 1996-11-07 | ||
FR9613585A FR2755367B1 (fr) | 1996-11-07 | 1996-11-07 | Utilisation d'un extrait de potentille erecta dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie |
PCT/FR1997/001988 WO1998019664A2 (fr) | 1996-11-07 | 1997-11-06 | Utilisation d'un extrait de potentilla erecta dans le domaine de la cosmetique et de la pharmacie |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001503754A true JP2001503754A (ja) | 2001-03-21 |
JP3654653B2 JP3654653B2 (ja) | 2005-06-02 |
Family
ID=9497418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52110698A Expired - Fee Related JP3654653B2 (ja) | 1996-11-07 | 1997-11-06 | 化粧品及び医薬品分野でのポテンチラ・エレクタ抽出物の使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US6193975B1 (ja) |
EP (1) | EP0946138B1 (ja) |
JP (1) | JP3654653B2 (ja) |
DE (1) | DE69719366T2 (ja) |
ES (1) | ES2193364T3 (ja) |
FR (1) | FR2755367B1 (ja) |
WO (1) | WO1998019664A2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004529162A (ja) * | 2001-05-10 | 2004-09-24 | コグニス・フランス・ソシエテ・アノニム | プロアントロシアニジンオリゴマーの使用 |
JP2008189669A (ja) * | 2007-01-30 | 2008-08-21 | Lvmh Recherche | 琥珀抽出物を含有する化粧用組成物 |
JP2009533401A (ja) * | 2006-04-14 | 2009-09-17 | エルブイエムエイチ レシェルシェ | 肌の手入れ用のすすぎ洗い可能なマスク型化粧品組成物 |
JP2017043575A (ja) * | 2015-08-28 | 2017-03-02 | 北海道三井化学株式会社 | 皮膚外用剤 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2779059B1 (fr) * | 1998-05-29 | 2004-09-10 | Guerlain | Procede de traitement cosmetique pour lutter contre les effets du vieillissement cutane; nouvelles compositions cosmetiques pour sa mise en oeuvre |
US6471972B1 (en) | 1996-11-07 | 2002-10-29 | Lvmh Recherche | Cosmetic treatment method for fighting against skin ageing effects |
CA2266188A1 (en) * | 1999-03-19 | 2000-09-19 | Stephen Chizick | Natural preparation for treatment of male pattern hair loss |
CA2394211A1 (en) * | 1999-12-15 | 2001-06-21 | Kyowa Hakko Kogyo Co., Ltd. | Stabilizers for sodium l-ascorbate-2-phosphate |
FR2828810B1 (fr) * | 2001-08-27 | 2005-10-07 | Lvmh Rech | Composition cosmetique a effet tenseur contenant un polymere d'origine naturelle et un agent hydratant polyhydroxyle |
US20050238730A1 (en) * | 2001-11-21 | 2005-10-27 | Agnes Le Fur | Compositions comprising an ethanolamine derivative and organic metal salts |
EP1398019A1 (de) * | 2002-09-13 | 2004-03-17 | Cognis France S.A. | Verfahren zum Schutz und zur Modulation von Dermal Epidermal Junctions |
CA2503489C (en) | 2002-10-25 | 2013-09-10 | Essentia Biosystems, Inc. | Modulation of zinc levels to improve tissue properties |
FR2886843B1 (fr) * | 2005-06-13 | 2007-08-17 | Am Phyto Conseil Sarl | Utilisation d'un extrait de griffonia, en particulier de griffonia simplicifolia dans une composition cosmetique ou dermatologique pour attenuer la pigmentation de la peau et des phaneres |
FR2918880A1 (fr) * | 2007-07-18 | 2009-01-23 | Seppic Sa | Utilisation d'un extrait de potentille comme actif cosmetique et pharmaceutique |
FR2921833A1 (fr) * | 2007-10-03 | 2009-04-10 | Seppic Sa | Utilisation d'un extrait de potentille comme actif cosmetique et pharmaceutique eclaircissant de la peau. |
WO2009121168A1 (en) * | 2008-04-01 | 2009-10-08 | Biopharmacopae Design International Inc. | Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3856941A (en) * | 1972-05-23 | 1974-12-24 | Sobel J | Astringent gel, its preparation and use |
US4014995A (en) * | 1973-09-19 | 1977-03-29 | The Quaker Oats Company | Cosmetics containing finely divided oat flour |
LU83173A1 (fr) * | 1981-02-27 | 1981-06-05 | Oreal | Nouvelles compositions cosmetiques pour le traitement des cheveux et de la peau contenant une poudre resultant de la pulverisation d'au moins une plante et un agent de cohesion |
JPH03188008A (ja) * | 1989-12-15 | 1991-08-16 | Shiseido Co Ltd | 化粧料 |
US5248503A (en) * | 1992-01-03 | 1993-09-28 | Emanuel King Rosalba | Herbal dietary supplement |
JP3415199B2 (ja) * | 1993-06-30 | 2003-06-09 | 三省製薬株式会社 | 皮膚外用剤 |
FR2734478B1 (fr) * | 1995-05-23 | 1997-07-11 | Berkem Sa | Composition cosmetique ou pharmaceutique utilisable par voie topique ou orale ayant des proprietes antiradicalaires et un pouvoir filtrant vis-a-vis des uv |
FR2749303B1 (fr) | 1996-05-30 | 1998-08-07 | Berkem Sa | Procede d'extraction de polyphenols catechiques a partir de potentilles extrait obtenu et son utilisation |
-
1996
- 1996-11-07 FR FR9613585A patent/FR2755367B1/fr not_active Expired - Lifetime
-
1997
- 1997-11-06 WO PCT/FR1997/001988 patent/WO1998019664A2/fr active IP Right Grant
- 1997-11-06 JP JP52110698A patent/JP3654653B2/ja not_active Expired - Fee Related
- 1997-11-06 EP EP97913260A patent/EP0946138B1/fr not_active Expired - Lifetime
- 1997-11-06 DE DE69719366T patent/DE69719366T2/de not_active Expired - Lifetime
- 1997-11-06 ES ES97913260T patent/ES2193364T3/es not_active Expired - Lifetime
- 1997-11-06 US US09/297,679 patent/US6193975B1/en not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004529162A (ja) * | 2001-05-10 | 2004-09-24 | コグニス・フランス・ソシエテ・アノニム | プロアントロシアニジンオリゴマーの使用 |
JP2009533401A (ja) * | 2006-04-14 | 2009-09-17 | エルブイエムエイチ レシェルシェ | 肌の手入れ用のすすぎ洗い可能なマスク型化粧品組成物 |
JP2008189669A (ja) * | 2007-01-30 | 2008-08-21 | Lvmh Recherche | 琥珀抽出物を含有する化粧用組成物 |
JP2017043575A (ja) * | 2015-08-28 | 2017-03-02 | 北海道三井化学株式会社 | 皮膚外用剤 |
Also Published As
Publication number | Publication date |
---|---|
ES2193364T3 (es) | 2003-11-01 |
WO1998019664A3 (fr) | 1998-08-13 |
WO1998019664A2 (fr) | 1998-05-14 |
FR2755367B1 (fr) | 2000-01-21 |
DE69719366T2 (de) | 2003-11-20 |
US6193975B1 (en) | 2001-02-27 |
EP0946138B1 (fr) | 2003-02-26 |
EP0946138A2 (fr) | 1999-10-06 |
FR2755367A1 (fr) | 1998-05-07 |
JP3654653B2 (ja) | 2005-06-02 |
DE69719366D1 (de) | 2003-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102513930B1 (ko) | 화장료 용도의 아니고잔토스 플라비두스 추출물 | |
JP5010775B2 (ja) | 化粧品及び皮膚科学におけるエラグ酸及びその誘導体の使用 | |
JP3654653B2 (ja) | 化粧品及び医薬品分野でのポテンチラ・エレクタ抽出物の使用 | |
CN111700853B (zh) | 一种具有抗敏修复功效的化妆品组合物及其应用 | |
JP7309620B2 (ja) | 皮膚及び/又は粘膜を水和させるためのネフェリウム・ラパセウム(nephelium lappaceum)の果皮の抽出物の使用 | |
JP2011516524A (ja) | 新規組成物およびその使用 | |
JP2002193738A (ja) | 皮膚老化の徴候を処置する組成物における、少なくとも1種のツツジ科植物の少なくとも1種の抽出物の使用 | |
WO1999018927A1 (fr) | Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait vegetal obtenu a partir du trefle (trifolium sp.) | |
US5955083A (en) | Use of eriobotrya japonica extract, in particular in cosmetics for stimulating glycosaminoglycan synthesis | |
JP2001513491A (ja) | エラスチン合成促進のためのジンセノシドRb1の使用 | |
CN108883055B (zh) | 非洲楝提取物的美容用途 | |
KR20040068986A (ko) | 줄기 세포 인자의 생산ㆍ방출의 억제에 의한 소양, 피부거칠어짐, 민감성 피부 개선용 및 미백용 약제 | |
KR100892888B1 (ko) | 표피세포에 있어서의 라미닌 5 생산능을 증강시킬 수 있는물질 및 이들의 사용 | |
JP2001513509A (ja) | 真皮エラスチン合成を促進するためのナルコユリ属抽出物の使用 | |
US20100040706A1 (en) | Method of anti-ageing cosmetic care by stimulation of survivin expression | |
JP2020518593A (ja) | 皮膚及び/又は粘膜の硬さを増大させるためのネフェリウム・ラッパセウム(Nephelium lappaceum)抽出物の使用 | |
JP2006316050A (ja) | 抗シワ剤 | |
JP3676813B2 (ja) | ベルトレティア抽出物を含有する化粧用又は薬用、特に皮膚科用組成物 | |
JP2008100943A (ja) | インスリン様成長因子−1分泌促進作用を有する皮膚外用剤 | |
KR101322850B1 (ko) | 박하잎 추출물, 밀싹 추출물 및 길경 추출물을 유효성분으로 포함하는 모공 축소 또는 피지분비 억제용 화장료 조성물 | |
KR101261731B1 (ko) | 콜라겐 생성 촉진용 피부 외용제 조성물 | |
KR20160003910A (ko) | 한약재 추출물을 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물 | |
US9023403B2 (en) | Use of a Lepechinia caulescens extract as a cosmetic agent, and cosmetic composition containing same | |
KR20180108255A (ko) | 파리신 비를 포함하는 화장료 조성물 | |
KR20180096094A (ko) | 코스모스 추출물을 포함하는 피부주름 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040601 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20040818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040824 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041102 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041126 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050201 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050301 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080311 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090311 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090311 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100311 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110311 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120311 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120311 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130311 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140311 Year of fee payment: 9 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |